Key Figures Q1 2020
|
SEK m, unless otherwise stated |
2020 Jan-Mar |
2019 Jan-Mar |
2019 Jan-Dec |
Δ 2019-2020 |
|
Net revenues |
175.0 |
174.3 |
844.8 |
0.4% |
|
Cost of goods sold |
-20.0 |
-25.3 |
-105.6 |
-21% |
|
Operating expenses |
-121.1 |
-147.9 |
-508.0 |
-18% |
|
EBIT |
34.0 |
1.1 |
231.2 |
2991% |
|
EBIT margin, % |
19.4 |
0.6 |
27.4 |
18.8 ppt |
|
EBITDA |
39.1 |
12.0 |
272.1 |
226% |
|
Earnings per share, before dilution, SEK |
2.38 |
0.41 |
6.33 |
483% |
|
Earnings per share, after dilution, SEK |
2.34 |
0.40 |
6.20 |
484% |
|
Cash flow from operating activities |
48.1 |
50.9 |
287.0 |
-5.6% |
|
Cash and cash equivalents |
861.4 |
647.4 |
816.8 |
33% |
Net revenues and EBIT per segment Q1 2020
|
SEK m |
Net Revenues |
EBIT |
||||
|
|
2020 Jan-Mar |
2019 Jan-Mar |
2019 Jan-Dec |
2020 Jan-Mar |
2019 Jan-Mar |
2019 Jan-Dec |
|
Zubsolv® US |
163.9 |
161.7 |
719.2 |
75.9 |
68.2 |
347.1 |
|
US Pharma – total |
163.9 |
161.7 |
719.2 |
75.9 |
68.2 |
347.1 |
|
Digital Therapeutics |
- |
- |
- |
-12.1 |
- |
-0.9 |
|
Digital Therapeutics– total |
- |
- |
- |
-12.1 |
- |
-0.9 |
|
Abstral® royalties |
8.6 |
10.9 |
112.6 |
- |
- |
- |
|
Edluar® royalties |
2.4 |
1.7 |
11.6 |
- |
- |
- |
|
Zubsolv - ex US |
0.1 |
0.0 |
0.1 |
- |
- |
- |
|
OX-MPI |
- |
- |
1.4 |
- |
- |
- |
|
HQ & Pipeline segment – total |
11.1 |
12.6 |
125.6 |
-29.9 |
-67.1 |
-115.0 |
|
Total |
175.0 |
174.3 |
844.8 |
34.0 |
1.1 |
231.2 |
Cash flow Q1 2020
|
SEK m |
Q1 2020 |
Q1 |
Jan - Dec 2019 |
|
Cash flow from operating activities |
48.1 |
50.9 |
287.0 |
|
Investment activities |
-3.9 |
-0.1 |
-22.4 |
|
Financing activities |
-68.8 |
-10.7 |
-53.7 |
|
Cash flow (excl exchange rate differences) |
-24.6 |
40.2 |
210.8 |
|
Liquid funds |
861.4 |
647.4 |
816.8 |
